The notices it replaced
- Reissues: PAR-16-300 Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3)
Replaced by PAR-19-329.
Who won it before
18 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $22,866,840 in first-year total cost, median $1,187,604.
Most frequent study sections
- Clinical Trials Review Study Section[CLTR (MA)]6
- Clinical Trials Review Study Section[CLTR (JA)]4
- Clinical Trials Review Study Section[CLTR (OA)]4
- Special Emphasis Panel[ZHL1 CSR-H (F2)]2
- Special Emphasis Panel[ZHL1 CSR-H (F1)]1
Most frequent institutions
- DUKE UNIVERSITY2
- CHILDREN'S HOSP OF PHILADELPHIA1
- CLEVELAND CLINIC LERNER COM-CWRU1
- EMORY UNIVERSITY1
- FRED HUTCHINSON CANCER RESEARCH CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | 1/2 Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients with Acute Respiratory Failure and Sepsis1UG3HL147011-01A1 | BOECKH, MICHAEL JLIMAYE, ABHIJIT PRAKASHRUBENFELD, GORDON DSTAPLETON, RENEE D | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $2,341,858 | CLTR |
| 2020 | 1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial)1UG3HL148560-01A1 | MORRIS, CLAUDIA R | EMORY UNIVERSITY, GA | $1,537,648 | ZHL1 |
| 2020 | 1/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED)1UG3HL147016-01A1 | DENNINGHOFF, KURT RMARTINEZ, FERNANDO D | UNIVERSITY OF ARIZONA, AZ | $1,466,425 | ZHL1 |
| 2020 | RACE-CARS CCC 1/21UG3HL146935-01A1 | GRANGER, CHRISTOPHER B. | DUKE UNIVERSITY, NC | $1,184,044 | CLTR |
| 2019 | 1/2 ICECAP: Influence of Cooling duration on Efficacy in Cardiac Arrest Patients1UG3HL145269-01A1 | GEOCADIN, ROMERGRYKOMEURER, WILLIAM JOSEPHSILBERGLEIT, ROBERT | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $4,438,938 | CLTR |
| 2019 | 1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)1UG3HL143192-01A1 | GLADWIN, MARK TTRIULZI, DARRELL J | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $1,459,550 | ZHL1 |
| 2019 | 1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA)1UG3HL141722-01A1 | FESTIC, EMIRGAJIC, OGNJENLEVITT, JOSEPH ERICMAHAFFEY, KENNETH W.MATTHAY, MICHAEL A. | STANFORD UNIVERSITY, CA | $1,419,180 | CLTR |
| 2019 | 1/2: An Anesthesia-Centered Bundle to Reduce Postoperative Pulmonary Complications: The PRIME-AIR Study1UG3HL140177-01A1 | FERNANDEZ-BUSTAMANTE, ANAVIDAL MELO, MARCOS F | MASSACHUSETTS GENERAL HOSPITAL, MA | $1,191,164 | CLTR |
| 2019 | 1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study1UG3HL145266-01A1 | MARTINEZ, FERNANDO JNOTH, IMRE | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $976,537 | CLTR |
| 2019 | 1/2 Pomalidomide for Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia (HHT)1UG3HL140097-01A1 | MCCRAE, KEITH R. | CLEVELAND CLINIC LERNER COM-CWRU, OH | $876,052 | CLTR |
| 2019 | 1/2 + PROmote weight loss in obese PAD patients to preVEnt mobility loss: the PROVE Trial1UG3HL141729-01A1 | MCDERMOTT, MARY MCGRAE | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $599,564 | CLTR |
| 2018 | 1/2 PROSpect: Prone and Oscillation Pediatric Clinical Trial (CCC)1UG3HL141736-01 · under PAR-16-300 | CHEIFETZ, IRA MCURLEY, MARTHA AQKNEYBER, MARTIN | UNIVERSITY OF PENNSYLVANIA, PA | $1,718,755 | ZHL1 |
| 2018 | Impact of Low Flow Nocturnal Oxygen Therapy On Hospital Readmission/Mortalityin Patients with Heart Failure and Central Sleep Apneal (LOFT-HF)1UG3HL140144-01 · under PAR-16-300 | ABRAHAM, WILLIAM TOBER | OHIO STATE UNIVERSITY, OH | $742,108 | CLTR |
| 2018 | Transfusion of Prematurity Early School Age Follow-up (TOP 5) CCC1UG3HL143204-01 · under PAR-16-300 | DEMAURO, SARA BONAMONOPOULOS, PEGGY C | UNIVERSITY OF IOWA, IA | $633,736 | CLTR |
| 2018 | 1/2 A comparison of individualized vs. weight based protocols to treat vaso-occlusive episodes in Sickle Cell Disease (COMPARE VOE)1UG3HL137856-01A1 · under PAR-16-300 | TANABE, PAULA | DUKE UNIVERSITY, NC | $431,577 | CLTR |
| 2018 | 1/2 A randomized controlled trial of pravastatin to prevent preeclampsia in high-risk women1UG3HL140131-01 · under PAR-16-300 | COSTANTINE, MAGEDLAWRENCE CLEARY, KIRSTENSAADE, GEORGE R.WAPNER, RONALD | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $153,314 | CLTR |
| 2017 | 1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL)1UG3HL138325-01 · under PAR-16-300 | VEDANTHAM, SURESH | WASHINGTON UNIVERSITY, MO | $1,376,983 | CLTR |
| 2017 | 1/2 Hydrocortisone for BPD Respiratory and Developmental Outcomes Study (HYBRiD Outcomes Study): Clinical Coordinating Center1UG3HL137872-01 · under PAR-16-300 | DEMAURO, SARA BONAMOHINTZ, SUSANKALLAPUR, SUHASKIRPALANI, HARESH | CHILDREN'S HOSP OF PHILADELPHIA, PA | $319,407 | CLTR |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.